IGENE BIOTECHNOLOGY INC
OOTC:IGNE0.00
USD
0.00
(0.00%)
ISIN
US4516951005
CUSIP
451695100
Return %
Stock
S&P 500
1Y
0.00
14.20
3Y
-99.00
81.12
5Y
-99.00
68.34
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.Company Description
- CEO
- Joseph L. Downs
- Full Time Employees
- 18
- Sector
- Process industries
- Industry
- Chemicals: agricultural
- Address
- 9110 Red Branch Road Columbia MD United States 21045
- IPO Date
- Jul 29, 1986
- Website
- igene.com
- Similar Companies
- Business
- Igene Biotechnology, Inc. Igene Biotechnology, Inc. (IGNE) engages in the research, development, production, and commercialization of specialty ingredients for human and animal nutrition. The company supplies natural astaxanthin, marketed as AstaXin and produced from yeast, serving as a nutrient and pigment source for coloring farmed salmon and trout species; it also provides ingredients and finished products to the nutraceutical and animal feed industries, alongside research and development services encompassing microbial strain improvement, fermentation process development and scale-up from shake flasks to commercial fermentors, and analytical chemistry services for carotenoid identification and quantification in foods, feeds, and animal tissues, including verification of wild versus farmed salmonids. Founded in 1981 and headquartered at 9110 Red Branch Road, Suite J, Columbia, Maryland, the company operates primarily in the United States with worldwide marketing of its fermentation technology, nutrition, and health applications. Formerly known as IGI Biotechnology, Inc., it changed its name to Igene Biotechnology, Inc. in April 1986. In recent developments, the company has secured strategic partnerships and funding to support R&D initiatives, enhancing its product pipeline and market position in the biopharmaceutical and agricultural inputs sectors.